anti-Cortactin, pAb

CHF 322.00
In stock
YIF-LF-PA0203100 µlCHF 322.00
 
More Information
Product Details
Synonyms EMS1; CTTN; Amplaxin; Oncogene EMS1; Src Substrate Cortactin
Product Type Polyclonal Antibody
Properties
Immunogen/Antigen Synthetic peptide.
Application Western Blot (1:5,000)
ELISA not tested.
Crossreactivity Human
Rat
Purity Detail Protein A purified.
Concentration 1 mg/ml
Formulation Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Other Product Data Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
Declaration Manufactured by AbFrontier
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS No
Product Specification Sheet
Datasheet Download PDF
Cortactin is a ubiquitous actin-binding protein that was originally identified as a substrate for Src. It is accumulated in peripheral, actin-enriched structures of cells, including lamellipodia and membrane ruffles, suggesting that cortactin facilitates actin network formation. Cortactin has four major domains of interest:the N-terminal acidic (NTA) and tandem repeats domains, and the C-terminal proline-rich and SH3 Domains. NTA associates with the Arp2/3 and WASP complex at F-actin branches. Cortactin is involved in promoting cell motility and invasion, including a critical role in invadopodia, actin rich-subcellular protrusions associated with degradation of the ECM by cancer cells. Cortactin is phosphorylated by src family kinases at Y421, Y466, and Y482 and S405 and S418 that are phosphorylated by Erk family kinases. May contribute to the organization of cell structure. The SH3 motif may function as a binding region to cytoskeleton. Tyrosine phosphorylation in transformed cells may contribute to cellular growth regulation and transformation.
Product References
1) Ammer AG and Weed SA, (2008) Cell Motil Cytoskeleton 65(9):687-707. (General)
2) Weaver AM, (2008) Cancer Lett 265(2):157-66. (General)
3) Buday L and Downward J, (2007) Biochim Biophys Acta 1775(2):263-73. (General)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.